G aucher disease (GD) is the commonest lysosomal storage disorder (LSD) with an estimated global incidence of 1: 40,000 to 1:60,000 live births [1] . The metabolic defect is a deficiency of acid β-glucosidase (lysosomal glucocerebrosidase) due to biallelic mutations in GBA gene that results in the accumulation of glucocerebroside in lysosomes, classically in tissue macrophages; other cell types involved in disease pathophysiology include immune cells, osteoblasts and hepatocytes [2] .
Glucocerebroside-laden macrophages (Gaucher cells) accumulate throughout the body and this is the hallmark of multi-systemic disease manifestations. The severity and pattern of organ involvement is highly heterogeneous and only partly explained by GBA mutations.
Gaucher disease represents a prototype of rare lysosomal diseases for development of diagnostic and management algorithms based on regional characteristics
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as well as transformative therapies, including Enzyme replacement therapy (ERT) and recently approved, oral Substrate reduction therapy (SRT). In case of diagnostic delay, patients suffer from disabling and potentially lifethreatening complications. Hence, it is important to diagnose and manage Gaucher disease in a timely and optimal manner. We herein provide guidelines and recommendations for an optimal approach to diagnosis and management of Gaucher disease in Indian patients.
GAUCHER DISEASE IN INDIA
Gaucher disease is a pan-ethnic disorder; although, most published literature is almost entirely focused on Caucasian patients [4] . Due to the tradition of consanguineous marriages in parts of the country, it seems likely that the frequency of Gaucher disease may be higher in India. Of more than 300 mutations catalogued in Gaucher disease, L444P appears to be the most prevalent in India [5] . This mutation occurs normally in the pseudogene sequence; vulnerability of GBA locus to gene conversion events underlies relatively high prevalence of this mutation world-wide. We have found that homozygosity for L444P mutation is most common genotype in most parts of the country while in the northern region, in addition to L444P, there is a relatively higher rate of rare private mutations [5, 6] . Homozygosity for L444P mutation typically results in neuronopathic disease but within this group there is extreme variation, which can range from lethal collodion skin baby phenotype at birth to a less severe type III phenotype with minimal oculomotor apraxia as the sole neurologic abnormality [7] . Knowledge of GBA genotype of individual patients is helpful to guiding optimal monitoring, estimating prognosis, timing of enzyme therapy and genetic counseling.
Traditionally, Gaucher disease patients are classified into three broad phenotypes based on the presence or absence of neurological manifestations and their severity ( Table I) . However there is a continuum of phenotypes, ranging from mildly affected adults to the severe, lifethreatening manifestations of type 2 patients presenting with non-immune hydrops fetalis and neurodegenerative disease [8] . Patients with type 1 Gaucher disease in India present from as early as infancy to late childhood with a median age of 3.6 years [9] . This highly aggressive phenotype with spleno-hepatomegaly, cytopenia, irritability, bone involvement and failure to thrive is associated with early mortality without treatment [10] . The common differential diagnosis of the most prevalent presenting phenotype of splenohepatomegaly in Gaucher disease include hemolytic anemias typically hemoglobinopathies, non-cirrhotic portal hypertension, tropical splenomegaly, lymphoreticular malignancies and [11] . The earliest and most common neurological manifestation in these patients includes oculomotor apraxia. This ocular sign must be evaluated in each patient at every clinic visit as it may help to distinguish between Type 1 and type 3 GD [4] . A perinatal lethal variant is a severe manifestation presenting in utero or at birth as non-immune hydrops fetalis, isolated fetal ascites, collodion baby and hepatosplenomegaly [8, 12] . A high index of suspicion is important to delineate this phenotype in such cases to help families through appropriate genetic counseling.
The multisystem involvement in GD may result in complications that involve multiple organ systems [10, [13] [14] [15] [16] [17] [18] . These are common to all types of GD with the exception of neurological disease that is typically seen in type 2 and type 3 GD with milder manifestations in the latter (Box 1). Multispecialty referral is tailored dependent on the manifestations and complications encountered in the patient.
RECOMMENDATIONS

Investigations in a Suspected Patient
Enzyme diagnosis: The gold standard for diagnosis of Gaucher disease is acid β-glucocerebrosidase enzyme assay in blood leucocytes; Gaucher disease patients have levels ≤10% of controls. The sample should be collected in ethylenediaminetetraacetic acid (EDTA) or heparin vacutainers. An alternative that overcomes logistical difficulties in sending blood samples across long distances to arrive in good condition at the laboratory is dried blood spots (DBS). This is the recommended sample for GD diagnosis in India [19] .
Collection of sample needs to be optimal to avoid false results. Cultured skin fibroblasts may occasionally be required for enzyme activity estimation in cases where the blood reports are ambiguous; latter may arise in rare cases of Gaucher disease due to saposin deficiency or GBA mutations that lead to trafficking defect of the mutant enzyme (i.e., G202R) [20] or when the differential diagnosis include Niemann Pick type C disease, a disorder that may be associated with falsely low acid β-glucosidase activity [21] . Carrier-testing by assay of enzyme activity is unreliable because of overlap in enzyme activity between carriers and non-carriers [22] .
Molecular diagnosis: Molecular testing and identification of the GBA mutation confirms the diagnosis and in addition the genotype information aids prognostication, carrier-testing and prenatal diagnosis. These benefits are especially valuable in managing Gaucher disease in India due to high prevalence of L444P mutation, homozygosity for which is associated with neuronopathic disease, type 2 or type 3 [5] . We recommend GBA mutation analysis before initiation of therapy. However, there are >300 known GBA mutations catalogued in Gaucher disease and full gene sequencing is required when one or both alleles are other than L444P [23] . Based on published data and experience with patients followed in India, initial testing for L444P and full sequencing of the entire coding regions of GBA only when the patient tests negative for this common mutation in either of the two alleles is cost-effective.
Role of tissue biopsy:
The common presentation of hepatosplenomegaly with the hematological manifestations in GD patients overlaps other disease phenotypes for which bone marrow aspiration/biopsy are indicated. Gaucher cells in the marrow are classically described in GD; however, their presence or absence does not confirm or preclude the diagnosis of GD. Distribution of Gaucher cells is patchy and not uniform and likely to be missed, especially in aspiration biopsy. Moreover, pseudo-Gaucher cells have been described in disorders unrelated to GD i.e., thalassemia, HIV, mycobacterial infection in immunodeficient patients, and hematological malignancies [24] [25] [26] . Hence incidental finding of Gaucher cells during work-up of patients mandates enzyme activity measurement. At times, patients undergo liver biopsy after initial presentation with hepatosplenomegaly and mildly elevated liver enzymes. We do not recommend liver biopsy in Gaucher disease for diagnosis due to prohibitive bleeding risk from thrombocytopenia and coagulopathy. It is recognized that patients undergo splenectomy for a misdiagnosis of malignancy or another disorders [27] . We strongly advise that any patient who is considered for splenectomy for splenomegaly of uncertain diagnosis, mandatory enzymatic testing for lysosomal storage disorders like Gaucher and Niemann Pick disease be performed. This is important as splenectomy in Gaucher disease leads to acceleration of disease in the skeleton, liver and the lungs [28] .
Biomarkers in GD:
The expert group recommends serial biomarker measurement for longitudinal follow up of all patients to assess disease status. Chitotriosidase and CCL18 have been validated as representative of total body burden of Gaucher cells [29] . The most widely used biomarker in GD is chitotriosidase that is secreted by Gaucher cells. Although serum chitotriosidase is also elevated in several other lysosomal diseases and in thalassemia, the extraordinary elevations of chitotriosidase up to 1000-fold are only seen in Gaucher disease. A relative disadvantage is the presence of a polymorphism in the cognate gene CHIT1; about 6% of most ethnicities are homozygous for a null polymorphism and have undetectable chitotriosidase level. Some 30% of individuals are heterozygous for the polymorphism and their chitotriosidase is approximately one-half of that in patients homozygous wild type for the polymorphism [30] . In patients homozygous for null CHIT1 polymorphism, CCL18/PARC that is not subject to genetic variation is a useful alternative biomarker. However, currently this is not available in India. Recently, glucosylsphingosine has been validated as key biomarker of Gaucher disease, that directly reflects rootcause of the disease, and is involved in mediating disease pathophysiology [31] .
Management
Management of Gaucher disease needs a multidisciplinary approach and is best coordinated at a center with expertise in this complex disease. The multidisciplinary team generally includes a hematologist, geneticist, gastroenterologist, pediatrician, neurologist, occupational therapist and orthopedic surgeon.
Baseline Assessments
After confirmation of diagnosis, baseline evaluation to establish the extent and severity of the disease is recommended (Table II) . This incorporates an exhaustive general physical and neurological examination. Recommended investigations include a complete and differential blood count, liver function tests, serum calcium, 25-hydroxy-vitamin D, coagulation profile, biomarkers, assessment of liver and spleen size and bone by magnetic resonance imaging (MRI), if feasible. Ultrasound scanning for spleen and liver volumes and focal defects in the parenchyma is less expensive [32] . For children, a routine MRI of femurs to assess for marrow infiltration is not recommended due to normal cellular marrow in this age group that cannot be distinguished from pathological infiltration. However, when a patient Baseline plain chest and spinal radiograph should be performed to assess for pulmonary infiltration and early spinal deformity, which occur commonly in L444P homozygous patients. DEXA scan to document bone mineral density is ideal due to prevalent osteopenia and fragility fractures in GD, and should be performed if resources are available. Appropriate assessment for pulmonary vascular involvement includes Doppler 2D echocardiography (recommended only in asplenic patients) and high resolution CT Scan chest (HRCT) as there is high risk of pulmonary hypertension in splenectomized Gaucher disease patients. Further followup is indicated based on presence of elevated right ventricular systolic pressure in baseline echocardiography [33] .
Disease-specific Management
The disease specific management of GD includes enzyme replacement therapy (ERT) and substrate reduction therapy (SRT).
Enzyme Replacement Therapy:
The development and availability of ERT since 1991 as a treatment modality has transformed the natural course of the disease in patients affected with GD. Therapy with ERT significantly ameliorates organomegaly and improves hematological manifestations [34] [35] [36] , as also the skeletal manifestations, prevent avascular necrosis, and reverse, growth failure in Gaucher disease type 1 [37] [38] [39] . A longitudinal cohort study of 25 children with GD1 and GD3 with 14 years follow-up reinforced previous reports and showed sustained improvement in hemoglobin, platelet count and bone pain [40] . Generally, patients with Gaucher disease in India are more severely affected than in the West with earlier onset and more severe disease manifestations. Treatment with ERT should be considered even if avascular osteonecrosis has occurred, as studies have shown that risk of such complications is reduced with ERT [41, 42] . However, in setting of progressive neurological symptoms such as seizures and or/ neuroregression, ERT is not recommended, as it cannot cross the blood brain barrier. ERT with the recombinant enzyme, Imiglucerase is approved in India and is used for the treatment of patients with a confirmed diagnosis of type 1 GD and the visceral manifestations of type 3 GD. As the cost of therapy is high, stringent criteria have been formulated and are recommended to identify patients who would best benefit from ERT and optimize the outcome of therapy. Box 2 lists the criteria for initiation of ERT.
Although one or more criteria are needed to initiate therapy, in clinical practice most patients commonly present with significant multisystem involvement and have a combination of features making early intervention important. Waiting for the manifestations to progress before initiation will limit the benefit of the treatment and may lead to further deterioration with time [43] . The therapeutic goals that can be attained with ERT should be discussed at length with the patient and the family. In addition to the criteria to initiate enzyme replacement therapy, it is important to discuss with the family and the patient, the need to have life-long intravenous infusions every other week in hospital setting. The final decision on the candidacy of a patient for ERT needs assessment by the physician, that the family and patient will comply with this regimen. In our experience we have noted that some families cannot / are not willing to cope with this additional burden of frequent hospitalization and in this setting it is not wise to embark on enzyme treatment.
Administration of ERT:
ERT is a lifelong therapy and administered as an intravenous infusion once every 14 days. Being a recombinant enzyme and requiring reconstitution before infusion, precautions as mentioned in the pack insert should be strictly adhered to achieve the optimum activity of the drug. The standard dose for ERT at initiation is 60 units per kg bodyweight. However,
BOX 2 CRITERIA FOR INITIATION OF ENZYME REPLACEMENT THERAPY
ERT should be initiated in all symptomatic patients with one or more of the following features:
• Failure to thrive (height and weight less than the 5 th centile of age after excluding other causes)
• Splenohepatomegaly causing mechanical discomfort or splenic infarctions
• Severe cytopenia (Bicytopenia at least):--Hemoglobin <8 mg/dL) due to GD and not to other causes -Platelets <60,000/µL -Leucocyte count <3,000/mm 3 • Symptomatic bone disease (bone pain, bone crisis), or active bone disease (osteopenia, fractures, marrow infiltration, infarction, osteonecrosis)
• Prior splenectomy (history of splenectomy is a marker for disease severity and such patients carry a high risk of avascular necrosis and osteonecrosis)
• Symptomatic pulmonary involvement (evidence of pulmonary hypertension on 2D echocardiography, or evidence of Infiltrative lung disease on CT chest) VOLUME 55 __ FEBRUARY 15, 2018 PURI, et al.
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due to the heterogeneous nature of the disease manifestations, individualized dose modifications on a specific need-basis may be required [43] . If drug availability is limited, an initial dose of 30 units per kg may be used for less severely affected children, but should be increased if treatment goals are not met [44] . The weight of the patient is checked at each assessment and the dose adjusted according to the bodyweight. Total dose to be administered at each infusion can also be partly adjusted based on the need to avoid wastage of the reconstituted drug as the drug is expensive and under no circumstances should be wasted. Pre-infusion medication with antihistaminic/antipyretics is not routinely recommended unless there is history of infusion related reactions. Use of low-protein binding 'in-line' filters of 0.2 microns size is recommended for infusion.
Recommendations on Therapeutic Goals
The multisystem nature of the disease necessitates organ-specific therapeutic goals for patients on treatment. It is essential to set realistic expectations on improvement of the disease phenotype and discuss this with the family prior to initiation of therapy. Patients are followed up based on the clinical features at the time of presentation with a detailed evaluation at each visit to assess the improvement of disease manifestations as a response to therapy. Table III details the therapeutic goals for patients with GD and their expected timelines of achievement with therapy.
Adverse events with ERT:
The ERT in GD is generally well tolerated with few reported adverse events [45, 46] . Most adverse events reported are mild and include nausea, vomiting, fever, rash, headache, dyspepsia, diarrhea, headache and dizziness. Local infusion-site reactions may include itching, swelling and discomfort. Anaphylactic reactions have been reported in rare cases and necessary emergency medications must be available prior to infusion in cases at risk. Management of infusion-related reactions include stopping the infusion temporarily and administration of antihistaminic and/or antipyretics. In such cases, the infusion can be restarted slowly after the infusion-related reaction settles down. Severe reactions may need management with steroids.
Indian Experience with Enzyme Replacement Therapy
ERT with Imiglucerase has been in use in India since last 15 years. 75 GD patients have received therapy with Imiglucerase. It has been found to be highly effective and safe, with marked reversal of growth failure, cytopenia, visceral disease and amelioration of skeletal disease [9] . Timely initiation of ERT in these patients has improved the general well-being, growth, and prevented development and progression of complications [47] .
Substrate reduction therapy: Substrate reduction therapy (SRT) for GD is based on the principle of using inhibitor of glucosylceramide synthase, the rate-limiting enzyme in synthesis of glucosylceramide to balance residual activity of acid β-glucosidase due to GBA mutations. Eliglustat tartrate is an oral SRT that is a powerful and specific inhibitor of glucosylceramide synthase and was approved in US and many other countries as first-line oral therapy in adults with GD type 1 following an extensive clinical trial program since 2007 involving >400 patients. It has shown good safety profile and proven to reverse hematological visceral and skeletal disease, similar to ERT [48] . This promises to be a good option in India, where logistics of life-long 2-weekly intravenous infusions can be challenging, especially in rural areas with limited facilities. For all therapies in GD, excellent compliance is essential.
Supportive Management
This is an extremely important part of management of patients with GD, especially children affected with the disease. It includes correction of nutritional anemia, vitamin D deficiency and improvement of the nutritional status of the paient. Bisphosphonates can be administered if severe osteopenia co-exists. Immunization with vaccines as per the National guidelines and the recommended immunization schedule for splenectomized patients should be followed [49] . We have frequently encountered patients who present dependent on blood transfusions for severe anemia. This is marker of severe end-stage disease and each blood transfusion rarely lasts more that 2-3 weeks and transfused blood cells massively add to the load of glycolipids leading to rapid acceleration of the disease. Dependency on blood transfusion is an urgent indication for ERT with the goal to eliminate the need for blood transfusion. We also recommend withholding splenectomy if therapy with ERT/SRT is feasible in a particular patient, unless it is required as a life-saving measure.
Follow-up and Monitoring
All patients with GD, irrespective of the disease-specific treatment, must be followed up for evaluation of the disease status [32, 50] . . This should include assessment of all systems likely to be affected in GD. The recommended type and frequency of assessment is shown in Table II .
Hematopoietic Stem Cell Transplantation
Experience with hematopoietic stem cell transplantation (HSCT) is limited to about 50 cases of neuronopathic and non-neuronopathic GD. With the availability of ERT and its safety and efficacy profile, stem cell transplantation is Baseline platelet count between 60,000 -<120,000/µL:
-approach normal levels -the platelet count should increase by 1.5-to 2.0-fold/ approach normal levels 1 year -approach normal levels 2 years Baseline platelet count < 60,000/µL:
-the platelet count increase by 1.5-fold 1 year -continue to increase but normal counts may be unattainable 2-5 years Prevent fractures; attain bone mineral density commensurate with their age 1-2 years (z-score not t-score) 4 
Growth
Achieve normal weight and height as assessed by WHO growth charts for Indian Within 3 years children upto 10 years of age and BMI thereafter Achieve normal onset of puberty currently not in general use. A cochrane meta-analysis on the role of HSCT in GD [51] concluded that there were no clinical trials that have assessed HSCT safety and efficacy with that of the approved therapies for GD. A recent review [53] of the follow-up data of patients who underwent HSCT has suggested the need to re-evaluate this modality in selected patients in GD. However, there are no conclusive guidelines recommending the use of HSCT in GD [52] . Our group's consensus opinion is that BMT is not the treatment of choice for type 1 GD due to the associated risk of complications and mortality.
Genetic Counseling and Prenatal Diagnosis
GD is an autosomal recessive disorder with a 25% risk of recurrence in each pregnancy. Pre-test and post-test counseling must be done to ensure that the family understands the risk of disease in each pregnancy, the reproductive options to prevent recurrence, implications of giving birth to a child with GD, and the options available to them if the fetus is identified to be affected. VOLUME 55 __ FEBRUARY 15, 2018 [53, 54] .
When a child in a family is diagnosed with Gaucher disease, siblings should be screened. Those found to be affected but pre-symptomatic should be monitored to assess rate of progression, if any. There is wide phenotypic variation even among siblings; hence, presymptomatic diagnosis is not in itself an indication for therapy. These children should be monitored at 6-monthly intervals for development of cytopenia, splenomegaly and skeletal disease.
CONCLUSION
GD is an inherited pan-ethnic and the most common LSD that commonly manifests in childhood. Detection of β-glucocerebrosidase activity in leucocytes/cultured skin fibroblasts is considered as the most efficient and reliable
KEY MESSAGES FOR DIAGNOSIS AND MANAGEMENT OF GAUCHER DISEASE IN INDIA
• A high index of suspicion is essential for timely diagnosis.
• Leucocyte acid β-glucosidase activity is mandatory for establishing the diagnosis of Gaucher disease and can easily be performed by collecting 4-5 drops of blood on filter paper (similar to that available for newborn screening).
• GBA gene analysis for mutations is recommended to confirm the diagnosis and help identify patients at risk of neuronopathic disease.
• Initial screen for L444P mutation is recommended. In the absence of one of two L444P mutations, full sequencing of the entire coding regions of GBA is recommended.
• Prenatal testing is best performed by initial genotype determination in the affected proband, confirmation of obligate carrier state in the parents or by testing in family member under investigation.
• Bone marrow biopsy is not essential for diagnosis and the absence of Gaucher cells in the bone marrow does not exclude the diagnosis of Gaucher disease. Liver biopsy or splenectomy should not be performed in Gaucher disease.
• Chitotriosidase is a useful biomarker for serial monitoring of individual patients receiving ERT; it should be used in the context of other clinical indicators of disease activity. Chitotriosidase levels should not be used to compare disease severity among different patients.
• ERT should be considered in patients with Type 1 and Type 3 GD to address the visceral, hematological and skeletal manifestations. The clinical spectrum of L444P in India is extremely variable and detailed assessment for neurological involvement is important before consideration for ERT. ERT is not recommended in Type 2 Gaucher disease or severe type 3 Gaucher disease as the enzyme does not cross the blood brain barrier.
• The need for lifelong therapy and the commitment of the time, money and effort should be discussed in detail with the patient and the caregivers prior to initiation of therapy to ensure compliance.
• The optimum dose of ERT needs to be individualized in patients and will depend upon the body weight and response to ERT.
• Supportive therapy is of paramount importance in patients on or off definitive therapy.
• Genetic counseling forms the mainstay of prevention of future affected births. VOLUME 55 __ FEBRUARY 15, 2018 
